BMY · Company research
Bristol-Myers Squibb Co. (BMY): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
72records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait. | Bristol Myers Squibb offers a 4.2% dividend yield and trades at a significant valuation discount (9.5x forward earnings) compared to peers (15-20x). While the dividend alone is modest, the main investment thesis centers on the company's turnaround potential. If its growth portfolio successfully offsets legacy drug patent expirations, the stock could experience substantial rerating upside. The company's sub-40% payout ratio suggests dividend safety in the near term. | View source ↗ | The Motley Fool | Oct 20, 2026 | bullish | 1 | 1 |
| Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch | Pfizer will report Q3 2026 earnings on November 3, with focus on non-oncology segments. Eliquis demand is expected to boost Primary Care sales, while COVID-19 vaccine and Paxlovid revenues will decline. Specialty Care segment may see Vyndaqel growth offset by declines in Xeljanz and Enbrel due to competitive pressures. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.167 | 1 |
| Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? | BioNTech faces mounting clinical setbacks in its cancer vaccine pipeline, including a halted Phase 2 trial for autogene cevumeran and BNT113's failure to meet a primary endpoint in head and neck cancer trials. With COVID-19 vaccine revenues declining sharply (down 60% YoY) and the company unprofitable, investors must weigh the deep pipeline potential against significant uncertainty. The stock is recommended only for risk-tolerant investors. | View source ↗ | The Motley Fool | Oct 18, 2026 | neutral | 0 | 1 |
| Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline | BioNTech has 16.6 billion euros in cash and is advancing 14 pivotal oncology trials, positioning itself to transition from a COVID-19 vaccine maker to a major cancer treatment company. With a diversified pipeline including promising candidates like pumitamig and a $1 billion share repurchase program, the company has financial flexibility to fund development. However, risks include trial failures, declining COVID-19 revenue, and regulatory delays. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.2 | 1 |
| Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.167 | 1 |
| Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure? - Stocktwits | Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure? Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| Bristol Myers Squibb Company $BMY Stock: Curated Wealth Partners LLC Cuts Position - MarketBeat | Bristol Myers Squibb Company $BMY Stock: Curated Wealth Partners LLC Cuts Position MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| 31,005 Bristol Myers Squibb Company $BMY Shares Sold by Chiron Capital Management LLC - MarketBeat | 31,005 Bristol Myers Squibb Company $BMY Shares Sold by Chiron Capital Management LLC MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? | Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.8 | 1 |
| Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? | Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.8 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? | Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? | Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It | Bristol Myers Squibb (BMY) has been a trending stock but faces headwinds with shares down 11.1% over the past month. While the company maintains a Zacks Rank #3 (Hold) rating and trades at a valuation discount to peers, earnings estimates have declined 3.6% over the last 30 days. The company has a strong track record of beating consensus estimates but faces modest revenue growth projections of 3.4% for the current fiscal year. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It | Bristol Myers Squibb (BMY) has been a trending stock but faces headwinds with shares down 11.1% over the past month. While the company maintains a Zacks Rank #3 (Hold) rating and trades at a valuation discount to peers, earnings estimates have declined 3.6% over the last 30 days. The company has a strong track record of beating consensus estimates but faces modest revenue growth projections of 3.4% for the current fiscal year. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research | BMY Reports Mixed Phase III Trial Results, Stock Down Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 13, 2026 | neutral | 0 | 0.6 |
| BMY Reports Mixed Phase III Trial Results, Stock Down | Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| BMY Reports Mixed Phase III Trial Results, Stock Down | Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| BMY Reports Mixed Phase III Trial Results, Stock Down - TradingView | BMY Reports Mixed Phase III Trial Results, Stock Down TradingView | View source ↗ | TradingView | Oct 13, 2026 | neutral | 0 | 0.6 |
| Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run - Yahoo Finance | Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| BlackLine Honors Global Enterprise Leaders Transforming Financial Operations | BlackLine announced its 2026 Modern Accounting Awards, honoring six enterprise leaders—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for redefining financial operations through unified data architectures, intelligent automation, and agentic workflows. These organizations have eliminated tens of thousands of manual close hours and established continuous, audit-ready financial operations. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| BlackLine Honors Global Enterprise Leaders Transforming Financial Operations | BlackLine announced its 2026 Modern Accounting Awards, honoring six enterprise leaders—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for redefining financial operations through unified data architectures, intelligent automation, and agentic workflows. These organizations have eliminated tens of thousands of manual close hours and established continuous, audit-ready financial operations. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| Bristol Myers Squibb (BMY) Stock May Be Undervalued Despite Fresh Phase 3 Trial Wins - Simply Wall Street | Bristol Myers Squibb (BMY) Stock May Be Undervalued Despite Fresh Phase 3 Trial Wins Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today | Bristol Myers Squibb (BMY) closed down 2.58% to $57.60, underperforming the S&P 500. The company is set to report earnings on October 29, 2026, with projected EPS of $1.56 (down 4.29% YoY) and revenue of $12.54 billion (up 2.59% YoY). BMY trades at a Forward P/E of 8.7, below its industry average of 23.43, and holds a Zacks Rank #3 (Hold) rating with recent downward estimate revisions. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0 | 1 |
| Bristol Reverses Despite Double Win. But Its Key Rival Crashed. - Investor's Business Daily | Bristol Reverses Despite Double Win. But Its Key Rival Crashed. Investor's Business Daily | View source ↗ | Investor's Business Daily | Oct 12, 2026 | neutral | 0 | 0.6 |
| BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses - Yahoo Finance | BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Why Bristol Myers Squibb (BMY) Stock Is Down Today - Quiver Quantitative | Why Bristol Myers Squibb (BMY) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 12, 2026 | neutral | 0 | 0.6 |
| BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? | Bristol Myers Squibb (BMY) has outperformed the S&P 500 with a 35.8% gain over the past year, driven by strong performance from its Growth Portfolio including Opdivo Qvantig, Reblozyl, Camzyos, and Breyanzi. Recent FDA approvals like Zenbexus and positive pipeline progress offer long-term growth potential. However, the legacy portfolio faces continued generic competition, and much of the near-term optimism appears reflected in current valuations. Analysts recommend a cautious stance with a Hold rating. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | neutral | 0 | 1 |
| Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn - MarketBeat | Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| 53,744 Bristol Myers Squibb Company $BMY Shares Sold by Douglas Lane & Associates LLC - MarketBeat | 53,744 Bristol Myers Squibb Company $BMY Shares Sold by Douglas Lane & Associates LLC MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading - Stocktwits | MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY - Stocktwits | SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.167 | 1 |
| Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.167 | 1 |
| Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? | Bristol Myers Squibb (BMY) has demonstrated a strong track record of beating earnings estimates, with an average beat of 19.01% over the last two quarters. The company has a positive Earnings ESP of +1.12% and a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in its next report expected on October 29, 2026. Stocks with positive Earnings ESP and Zacks Rank #3 or better historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? | Bristol Myers Squibb (BMY) has demonstrated a strong track record of beating earnings estimates, with an average beat of 19.01% over the last two quarters. The company has a positive Earnings ESP of +1.12% and a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in its next report expected on October 29, 2026. Stocks with positive Earnings ESP and Zacks Rank #3 or better historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? | Bristol Myers Squibb (BMY) has demonstrated a strong track record of beating earnings estimates, with an average beat of 19.01% over the last two quarters. The company has a positive Earnings ESP of +1.12% and a Zacks Rank #2 (Buy) rating, suggesting another earnings beat is likely in its next report expected on October 29, 2026. Stocks with positive Earnings ESP and Zacks Rank #3 or better historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | neutral | 0 | 1 |
| Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | neutral | 0 | 1 |
| Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | neutral | 0 | 1 |
| Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now? | The American Century U.S. Quality Value ETF (VALQ) is reviewed as a reasonable smart beta option for investors seeking value exposure with broad diversification across 226 holdings. The fund has delivered 7.02% returns year-to-date and 10.23% over the past year, with a competitive 0.29% expense ratio. However, cheaper alternatives like iShares Core S&P U.S. Value ETF (IUSV) at 0.04% expense ratio and traditional market cap-weighted ETFs may be better for cost-conscious investors. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.286 | 1 |
| Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now? | The American Century U.S. Quality Value ETF (VALQ) is reviewed as a reasonable smart beta option for investors seeking value exposure with broad diversification across 226 holdings. The fund has delivered 7.02% returns year-to-date and 10.23% over the past year, with a competitive 0.29% expense ratio. However, cheaper alternatives like iShares Core S&P U.S. Value ETF (IUSV) at 0.04% expense ratio and traditional market cap-weighted ETFs may be better for cost-conscious investors. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.286 | 1 |
| Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity - Seeking Alpha | Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity Seeking Alpha | View source ↗ | Seeking Alpha | Oct 7, 2026 | neutral | 0 | 0.6 |
| 2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) | The article recommends two high-yield stocks for October: Bristol Myers Squibb (BMY) offering a 4.2% dividend yield despite facing near-term patent expiration challenges, and Realty Income (O) with a 6% yield and 31-year dividend increase streak, though facing headwinds from rising interest rates. Both stocks are trading at attractive valuations due to short-term concerns, presenting opportunities for long-term income-focused investors. | View source ↗ | The Motley Fool | Oct 7, 2026 | bullish | 1 | 1 |
| 2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) | The article recommends two high-yield stocks for October: Bristol Myers Squibb (BMY) offering a 4.2% dividend yield despite facing near-term patent expiration challenges, and Realty Income (O) with a 6% yield and 31-year dividend increase streak, though facing headwinds from rising interest rates. Both stocks are trading at attractive valuations due to short-term concerns, presenting opportunities for long-term income-focused investors. | View source ↗ | The Motley Fool | Oct 7, 2026 | bullish | 1 | 1 |
| Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward? | Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| BMY Stock Price Prediction 2026-2027 | Bristol Myers Squibb Forecast - 24/7 Wall St. | BMY Stock Price Prediction 2026-2027 | Bristol Myers Squibb Forecast 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Oct 7, 2026 | neutral | 0 | 0.6 |
| Can Redwire's Microgravity Pharma Work Create New Revenue Streams? | Redwire Corporation is expanding its microgravity capabilities into pharmaceutical research and development through its PIL-BOX platform, which enables protein-crystal growth in space. The company has launched 42 PIL-BOX units and recently entered a licensing agreement with ExesaLibero Pharma to receive royalties from commercial pharmaceutical products developed using its technology. Major pharmaceutical companies like Bristol Myers Squibb and Eli Lilly are also exploring microgravity for drug development. However, RDW stock trades at a premium valuation (4.94X forward P/S vs. 2.11X industry average) and holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| Can Redwire's Microgravity Pharma Work Create New Revenue Streams? | Redwire Corporation is expanding its microgravity capabilities into pharmaceutical research and development through its PIL-BOX platform, which enables protein-crystal growth in space. The company has launched 42 PIL-BOX units and recently entered a licensing agreement with ExesaLibero Pharma to receive royalties from commercial pharmaceutical products developed using its technology. Major pharmaceutical companies like Bristol Myers Squibb and Eli Lilly are also exploring microgravity for drug development. However, RDW stock trades at a premium valuation (4.94X forward P/S vs. 2.11X industry average) and holds a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock | Bristol Myers Squibb (BMY) is highlighted as a stock to watch with a Zacks Rank #2 (Buy) rating and a VGM Score of B. The company, a leading specialty biopharmaceutical firm, benefits from its blockbuster immuno-oncology drug Opdivo and efforts to revive its portfolio. With an attractive forward P/E ratio of 8.63 and recent positive earnings estimate revisions, BMY is recommended for value-focused investors. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock | Bristol Myers Squibb (BMY) is highlighted as a stock to watch with a Zacks Rank #2 (Buy) rating and a VGM Score of B. The company, a leading specialty biopharmaceutical firm, benefits from its blockbuster immuno-oncology drug Opdivo and efforts to revive its portfolio. With an attractive forward P/E ratio of 8.63 and recent positive earnings estimate revisions, BMY is recommended for value-focused investors. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain? - Simply Wall Street | Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA | Dollar General, Bristol-Myers Squibb, and Equinor ASA have received broker rating upgrades despite macroeconomic headwinds. All three stocks show positive earnings growth expectations and improved analyst sentiment, with Equinor showing the strongest projected earnings growth at 120.7% year-over-year. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA | Dollar General, Bristol-Myers Squibb, and Equinor ASA have received broker rating upgrades despite macroeconomic headwinds. All three stocks show positive earnings growth expectations and improved analyst sentiment, with Equinor showing the strongest projected earnings growth at 120.7% year-over-year. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters - Yahoo Finance | Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters Yahoo Finance | View source ↗ | Yahoo Finance | Oct 5, 2026 | neutral | 0 | 0.6 |
| Bristol Myers Squibb (BMY) withholds 2,332 shares for taxes as Cari Gallman's stock award vests. - Stock Titan | Bristol Myers Squibb (BMY) withholds 2,332 shares for taxes as Cari Gallman's stock award vests. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt - Investing.com | Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt Investing.com | View source ↗ | Investing.com | Oct 5, 2026 | neutral | 0 | 0.6 |
| Bristol Myers Squibb Falls as Analyst Downgrade Appears to Pressure Shares - Quiver Quantitative | Bristol Myers Squibb Falls as Analyst Downgrade Appears to Pressure Shares Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 5, 2026 | neutral | 0 | 0.6 |
| Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now? | Bristol Myers Squibb (BMY) is identified as a compelling value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company's valuation metrics, including a P/S ratio of 2.54 (below industry average of 6.12) and P/CF ratio of 7.95 (below industry average of 11.40), suggest the stock is undervalued relative to its earnings outlook. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 1 | 1 |
| Why is Bristol-Myers Squibb stock sliding today? - Investing.com | Why is Bristol-Myers Squibb stock sliding today? Investing.com | View source ↗ | Investing.com | Oct 5, 2026 | neutral | 0 | 0.6 |
| Agios' Growth Story Hinges on Mitapivat's Commercial Expansion | Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Agios' Growth Story Hinges on Mitapivat's Commercial Expansion | Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights | Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights | Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| 3 Reasons to Sell BMY and 1 Stock to Buy Instead - StockStory | 3 Reasons to Sell BMY and 1 Stock to Buy Instead StockStory | View source ↗ | StockStory | Aug 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.